Evidence map›Paper›PMID 39331676›Full record

ArticlePloS one2024

Simulation of cardiac arrhythmias in human induced pluripotent stem cell-derived cardiomyocytes.

Thea Bommer, Maria Knierim, Julia Unsöld, Dominic Riedl, Laura Stengel, Michael Paulus, Thomas Körtl, Norman Liaw, Lars S Maier, Katrin Streckfuss-Bömeke and 2 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Thea BommerDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Maria KnierimDepartment of Cardiothoracic and Vascular Surgery, University Medical Centre Göttingen, Göttingen, Germany.
Julia UnsöldInstitute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany.
Dominic RiedlJustus-Liebig-University Gießen Medical Clinic I and Campus Kerckhoff Bad Nauheim, Gießen and Bad Nauheim, Germany.ORCID 0009-0004-0920-7486
Laura StengelDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Michael PaulusDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.
Thomas KörtlJustus-Liebig-University Gießen Medical Clinic I and Campus Kerckhoff Bad Nauheim, Gießen and Bad Nauheim, Germany.
Norman LiawInstitute of Pharmacology and Toxicology, University Medical Centre Göttingen, Göttingen, Germany.
Lars S MaierDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.ORCID 0000-0001-9915-4429
Katrin Streckfuss-BömekeInstitute of Pharmacology and Toxicology, University of Würzburg, Würzburg, Germany.ORCID 0000-0001-5137-7228
Samuel SossallaJustus-Liebig-University Gießen Medical Clinic I and Campus Kerckhoff Bad Nauheim, Gießen and Bad Nauheim, Germany.
Steffen PabelDepartment of Internal Medicine II, University Hospital Regensburg, Regensburg, Germany.ORCID 0009-0000-1121-4889

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The effects and mechanisms of cardiac arrhythmias are still incompletely understood and an important subject of cardiovascular research. A major difficulty for investigating arrhythmias is the lack of appropriate human models. Here, we present a protocol for a translational simulation of different types of arrhythmias using human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CM) and electric cell culture pacing. The protocol comprises the handling of ventricular and atrial hiPSC-CM before and during in vitro arrhythmia simulation and possible arrhythmia simulation protocols mimicking clinical arrhythmias like atrial fibrillation. Isolated or confluent hiPSC-CM can be used for the simulation. In vitro arrhythmia simulation did not impair cell viability of hiPSC-CM and could reproduce arrhythmia associated phenotypes of patients. The use of hiPSC-CM enables patient-specific studies of arrhythmias, genetic interventions, or drug-screening. Thus, the in vitro arrhythmia simulation protocol may offer a versatile tool for translational studies on the mechanisms and treatment options of cardiac arrhythmias.

Indexed as

Arrhythmias, CardiacInduced Pluripotent Stem CellsMyocytes, CardiacCell DifferentiationCells, CulturedCell SurvivalHumans

Identifiers

PMID39331676
PMCPMC11432883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.